Stroke Pathophysiology, Models, and Therapies — Comprehensive Notes
Stroke Pathophysiology, Models, and Therapies — Comprehensive Notes
Overview of stroke and its consequences
Stroke occurs when flow to a region of the brain is interrupted briefly, causing rapid brain damage. In many cases, blood flow can drop by a large fraction in one hemisphere, often described as a reduction of approximately to in the affected area.
The rapid loss of blood flow leads to an acute cascade of events causing neuronal death in minutes to hours; in the cited model, neurons in the affected area can die quickly, with substantial death within the first few hours and by three days the affected core shows marked neuronal loss (blue region in the illustration).
Neuronal loss is typically difficult to reverse; once neurons are lost, functional recovery is limited, though partial restoration of some functions can be attempted with therapies aimed at preserving remaining tissue and promoting repair.
Clinically, stroke is a major global health problem with high incidence; in some regions, there are nearly a million cases per year in the US alone. Mortality varies by age and comorbidity (e.g., diabetes, hypertension). In many survivors, functional deficits persist (motor, cognitive, or other deficits).
Stroke models in the laboratory
Rodent models allow easy induction of stroke using a filament or suture to occlude the middle cerebral artery (MCA). A typical procedure: insert a suture through the common carotid artery to block the origin of the MCA; this creates a focal ischemia analogous to human stroke.
A one-hour occlusion followed by reperfusion (removal of the suture) mimics transient ischemia and reperfusion, allowing study of both the ischemic core and the penumbra.
In this model, the core area undergoes rapid neuronal death, while the surrounding tissue (penumbra) may be salvageable if protective strategies are applied promptly.
Major mechanisms driving early brain injury after stroke
It is not a single mechanism; multiple events act synergistically to kill neurons in the hours following a stroke.
Early events (minutes to hours): excitotoxicity, energy failure, ionic imbalance, edema formation.
Secondary processes (hours to days): inflammation, oxidative stress, and distress signals; later events include post-translational modifications and epigenetic alterations.
Excitotoxicity and energy failure (the early phase)
Excitotoxicity defined by excessive excitatory neurotransmitter release (glutamate and aspartate) leading to overactivation of receptors, especially NMDA receptors.
Following stroke, energy failure reduces neuronal energy supply, impairing neurotransmitter clearance and transporter function; this increases extracellular glutamate and receptor activation.
Excessive receptor activity causes an influx of calcium and other ions, activating proteases and inducible nitric oxide synthase, among other damaging pathways, driving neuronal death.
Early attempts to block glutamate release, receptor activation (notably NMDA receptors), or transporter reuptake were not successful clinically, in part because these events occur within minutes to hours and due to broad roles of glutamate signaling.
Edema, ionic imbalance, and membrane potential issues
Energy failure disables the Na^+/K^+-ATPase pump, which normally maintains ionic gradients and the resting membrane potential.
Resting membrane potential is typically around . When the pump fails, ionic gradients collapse, leading to cellular edema as water follows ions into cells.
The brain is particularly vulnerable to edema because it is enclosed within the rigid skull; edema raises intracranial pressure and can worsen injury.
The Na^+/K^+-ATPase pump uses a large fraction of brain energy; estimates indicate approximately of energy expenditure.
Loss of ionic gradients and cytotoxic edema contribute to the progression of injury in the hours after stroke.
Inflammation and blood–brain barrier (BBB) involvement
Stroke triggers an inflammatory response: resident microglia become activated, and peripheral immune cells may infiltrate the brain.
Brain inflammation is a double-edged sword: some inflammatory activity helps clear debris and promote repair, but excessive or prolonged inflammation exacerbates injury.
Endothelial activation and transient gaps can allow leukocytes to adhere and transmigrate into the brain, contributing to tissue damage via proteases and reactive oxygen species.
In the post-stroke brain, microglia become activated and can adopt phenotypes that either support healing or promote injury, depending on context.
Neutrophils (polymorphonuclear leukocytes) and other immune cells can accumulate in brain tissue within the first days, releasing proteolytic enzymes and reactive oxygen species that amplify damage if not controlled.
The balance of inflammation is critical: some inflammatory activity clears debris, but unchecked inflammation sustains injury.
Therapeutic strategies often aim to modulate inflammation and oxidative stress without completely blocking necessary cleanup processes.
Secondary and longer-term processes: ER stress and epigenetic regulation
ER stress and unfolded protein response can contribute to neuronal dysfunction after stroke; targeting ER stress may be beneficial when combined with other approaches.
Epigenetic changes also play a role in post-stroke biology, including DNA modifications and RNA-based regulation that alter gene expression without changing the DNA sequence.
Non-coding RNAs and microRNAs (miRNAs) after stroke
The brain shows extensive changes in non-coding RNAs after stroke; the majority of post-stroke transcriptome remodeling involves non-coding RNAs, including microRNAs (miRNAs).
Four major families of miRNAs are prominently expressed in the CNS and cerebrospinal fluid, contributing to a large portion of miRNA activity (percentages cited as 75-80% for these families).
miRNA-29 family, miRNA-140 family, miRNA-149 family (examples mentioned in the transcript) are among miRNA groups altered after stroke and implicated in post-stroke pathology.
A detailed case study highlighted microRNA-7 (miR-7):
After stroke, miR-7 levels decline (downregulated) for several days (roughly 3-5 days) and stay低 compared to baseline.
Knockout/deficiency of miR-7 worsens outcomes after stroke: motor deficits persist longer and brain damage is greater.
Restoring miR-7 levels (e.g., delivering synthetic miR-7) improved motor function and reduced brain damage in stroke-affected animals.
Mechanistically, miR-7 targets alpha-synuclein (SNCA), a protein linked to neurodegenerative diseases (Parkinson’s and some aspects of Alzheimer’s).
Stroke increases alpha-synuclein, likely because miR-7 is not there to suppress it; replenishing miR-7 reduces alpha-synuclein levels and is neuroprotective.
Experiments included behavioral tests (e.g., a sensorimotor task with a patched appendage, rotarod tests) showing improved function with miR-7 restoration.
Bioinformatics suggested miR-7 can regulate alpha-synuclein, providing a plausible mechanism for neuroprotection.
Directly reducing alpha-synuclein is also protective; miR-7 restoration may offer a more sustained, less toxic approach than direct targeting of SNCA.
Therapeutic implications: miRNA-based therapies are in clinical trials for stroke and other CNS conditions; modulating miRNAs offers a way to influence multiple downstream effectors with potentially broader impact than single-target drugs.
Epigenetic changes involving DNA methylation and hydroxymethylation
DNA methylation (5-mmC) generally suppresses gene expression when present at gene promoters; dynamic regulation of DNA methylation and demethylation occurs after stroke.
Hydroxymethylation (5-hmC) is produced by the TET family of enzymes (e.g., TET3) from 5-methylcytosine; 5-hmC is associated with active DNA demethylation and gene activation in many contexts.
In the peri-infarct region, 5-hmC levels rise quickly, which may represent a neuroprotective adaptation to support gene expression needed for recovery.
The enzyme TET3 mediates the conversion of 5-mC to 5-hmC; blocking TET3 dramatically worsens outcomes (high mortality and brain damage).
Vitamin C (ascorbate) is a strong cofactor that enhances TET enzyme activity, promoting 5-hmC formation.
Experimental findings:
Treating with ascorbate (ascorbate) increases 5-hmC levels and improves outcomes after stroke.
Co-treatment with a TET3 inhibitor blocks the ascorbate-induced increase in 5-hmC and negates the protective effect.
High-dose vitamin C (e.g., hundreds of milligrams to grams in animal studies) administered acutely after stroke improves neuronal survival and preserves brain structure.
Therapeutic implications: epigenetic and nucleotide-based therapies (e.g., targeting DNA methylation/hydroxymethylation via TET enzymes or vitamin C–mediated modulation) offer a potential strategy to influence the early post-stroke trajectory.
Neurodegeneration links and alpha-synuclein after stroke
Stroke acutely elevates alpha-synuclein, a protein central to Parkinson’s disease pathology, linking acute injury to a protein implicated in chronic neurodegenerative conditions.
miR-7 downregulation after stroke permits alpha-synuclein upregulation; restoring miR-7 suppresses alpha-synuclein and is neuroprotective.
Directly targeting alpha-synuclein (or indirectly via miR-7) appears protective in the stroke model, suggesting a shared mechanism with chronic neurodegenerative diseases.
Clinical therapies and current status
The only FDA-approved pharmacological therapy for acute stroke discussed is tissue plasminogen activator (tPA).
tPA works by dissolving clots to restore blood flow but has a narrow time window and benefits only a subset of patients.
Efficacy is highly time-dependent; optimal outcomes require administration within a limited period after stroke onset.
Response to tPA varies with comorbidities (e.g., diabetes) and genetic diversity, and in some patients tPA can worsen damage.
Other pharmacotherapies in development include anti-inflammatory and anti-oxidant strategies, which aim to reduce secondary injury due to inflammation and oxidative stress.
Some candidate compounds mentioned (and their caveats):
Sertraline/Sertralone-like compounds described as having anti-inflammatory/antioxidant properties in early-stage research; not established as standard stroke therapy.
General anti-inflammatory agents and antioxidants are being explored in clinical trials, with mixed results due to the dual roles of inflammation and oxidative stress in healing and injury.
There is ongoing interest in non-drug therapeutic approaches to limit injury and promote recovery, including physical and metabolic interventions (see below).
Non-pharmacological and physical therapies for stroke and recovery
Hypothermia (therapeutic cooling): lowers brain temperature by approximately 3-4°C to extend the therapeutic window for additional treatments.
Rodent data show reduced DNA damage and preserved tissue in cooled animals after stroke, along with improved functional recovery.
Mechanistic rationale includes decreased metabolic demand and reduced DNA damage/strand breaks.
Hyperbaric/hyperoxic therapies: hyperbaric oxygen exposure can enhance resistance to ischemia and reduce damage when used before or after stroke in animal models; supports oxygen delivery and may modulate inflammatory processes.
Caloric restriction and intermittent fasting: dietary interventions that reduce overall metabolic load and oxidative stress.
Traditional caloric restriction (e.g., 70% of normal intake in long-term studies) has shown reduced brain damage and improved recovery in stroke models and other animals; may extend lifespan and improve resilience.
Intermittent fasting (timed feeding) can be easier to adopt and still confers neuroprotection via upregulation of growth factors (e.g., BDNF) and other protective pathways; benefits are age-dependent:
In animal studies, intermittent fasting improves outcomes and reduces brain damage after stroke in younger animals.
Benefits appear to be diminished with advancing age (beyond mid-life in animals; equivalent human considerations around age and metabolic status).
Activity of growth factors: fasting regimens are associated with increased levels of neurotrophic and pro-survival factors (e.g., BDNF, IGF-1, possibly others) that support neuronal resilience and repair.
Stem cell therapies for stroke: potential and challenges
Early cell-based approaches aimed to transplant stem cells into the damaged brain to promote recovery.
Limitations observed in acute CNS injury, particularly in patients with comorbidities (e.g., diabetes, hypertension):
In diabetic or atherosclerotic conditions with vascular dysfunction, transplanted cells may preferentially enter damaged vessels or cause unintended vascular issues, including hemorrhagic transformation.
Transplanted stem cells can fail to integrate functionally or may contribute to adverse events if the host environment is highly inflammatory or poorly perfused.
Tumor risk with certain stem cell types (e.g., induced pluripotent stem cells, iPSCs) if cells continue to proliferate uncontrolled, especially with long-term follow-up; risk of tumor formation limits clinical translation.
Overall, stem cell therapies show promise in promoting repair but require careful patient selection, timing, cell type, and delivery approaches to minimize risks in stroke patients.
Integrative view and future directions
Stroke pathophysiology involves a network of interrelated processes occurring over minutes to days: excitotoxicity, energy failure, edema, inflammation, oxidative stress, and epigenetic changes.
A single drug is unlikely to be universally effective; combinatorial or multi-target approaches that address several pathways simultaneously may be essential.
Small-molecule, nucleotide-based, and epigenetic therapies (e.g., modulation of miRNAs, DNA hydroxymethylation via TET enzymes, vitamin C–mediated epigenetic changes) offer potential avenues for neuroprotection and functional recovery.
Non-drug strategies (hypothermia, hyperbaric oxygen, caloric restriction/intermittent fasting) provide complementary means to reduce injury and enhance endogenous repair mechanisms.
The clinical path forward involves identifying patient subgroups most likely to benefit from specific interventions, optimizing timing windows, and combining therapies to maximize functional outcomes while minimizing adverse effects.
Key takeaways for exam preparation
Stroke causes rapid and multifactorial brain injury; early is critical, with substantial neuron loss occurring within hours.
Experimental stroke models (e.g., MCA occlusion in rodents) help study core vs. penumbra and test interventions.
Excitotoxicity, energy failure, and edema are immediate drivers of injury; inflammation and oxidative stress amplify damage over days.
Epigenetic changes, including DNA hydroxymethylation (5-hmC) and miRNA regulation (notably miR-7), influence gene expression and neuronal survival after stroke; targeting these pathways is an active research area.
Alpha-synuclein links between acute stroke and neurodegenerative disease pathways offer a plausible mechanism for longer-term pathology and a target for intervention via miR-7 or direct SNCA modulation.
Clinically approved therapy remains mainly tPA, with significant restrictions; most promising approaches are combination strategies and non-drug interventions.
Non-pharmacological strategies (hypothermia, HBOT, intermittent fasting) can modulate injury/repair processes and may extend therapeutic windows or improve recovery.
Stem cell therapies show potential but face substantial translational hurdles (timing, safety, tumorigenicity, metabolic comorbidities).
Formulas and numerical references
Brain blood flow drop in affected hemisphere:
Resting membrane potential:
Na^+/K^+-ATPase energy usage:
Role of tPA: tissue plasminogen activator (FDA-approved clot-dissolving therapy) with time-window limitations (not explicitly numerical in transcript, but context is time-sensitive).
Hydroxymethylation and TET enzymes: 5-hmC is produced from 5-methylcytosine (5mC) via TET enzymes (e.g., TET3); ascorbate (Vitamin C) enhances TET activity and raises 5-hmC levels; inhibition of TET3 worsens outcomes.
Intermittent fasting effects: increases neurotrophic factors (e.g., BDNF) and other protective pathways; benefits are age-dependent in models (stronger when started younger).
Notes on terminology and context
The transcript contains some informal phrasing and minor inconsistencies (e.g., “EPA” likely referring to tPA; some drug names described with nonstandard terminology). The core concepts align with established stroke biology: acute ischemia triggers excitotoxicity and energy failure, followed by edema, inflammation, and later epigenetic changes; therapies aim to protect tissue and promote recovery, with non-drug approaches and epigenetic/nucleic-acid strategies showing promise in preclinical work and early clinical trials.